-

IMPLANET Announces Its 2022 Financial Calendar

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:

IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specialized in vertebral implants, today announces its schedule for the publication of financial information for 2022Etats-Unis de son expansion commerciale aux Etats-Unis,.

Event

Dates*

2021 Full-Year Results

March 15, 2022

2022 First-Quarter Revenue

April 19, 2022

Annual General Meeting

April 26, 2022

2022 First-Half Revenue

July 11, 2022

2022 First-Half Results

September 20, 2022

2022 Third-Quarter Revenue

October 18, 2022

(*): These dates can be subject to modifications. Press releases will be published after market close.

Upcoming financial event:
2021 Full-Year Results, on March 15, 2022 after market close.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 29 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.implanet.com.

The Company would like to remind readers that the table for monitoring the equity line (OCA, BSA) and the number of shares outstanding is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

Contacts

IMPLANET
Ludovic Lastennet, CEO
David Dieumegard, CFO
Tel.: +33 (0)5 57 99 55 55
investors@Implanet.com

NewCap
Investor Relations
Mathilde Bohin
Nicolas Fossiez
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.eu

NewCap
Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.eu

IMPLANET

BOURSE:ALIMP

Release Versions

Contacts

IMPLANET
Ludovic Lastennet, CEO
David Dieumegard, CFO
Tel.: +33 (0)5 57 99 55 55
investors@Implanet.com

NewCap
Investor Relations
Mathilde Bohin
Nicolas Fossiez
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.eu

NewCap
Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.eu

More News From IMPLANET

Minutes of IMPLANET’s Annual General Meeting Held on April 17, 2026

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth : ALIMP, FR0013470168, éligible PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, informs its shareholders that its Annual General Meeting was held on Friday, April 17, 2026, at 2:00 p.m. CEST at the Company's registered office, in Martillac (FRANCE). The number of shares held by shareholders present, represented or havin...

IMPLANET Reports Q1 2026 Revenue of €3.03 Million, up 18%

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its revenue for the first quarter of 2026. Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: “This first quarter of 2026 marks a new step in IMPLANET’s growth momentum, with revenue up 18% compared with the sa...

IMPLANET Receives FDA Clearance in the United States for the 3D Cage Range – Swingo™

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announces that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Swingo™ anterior cervical cage. Developed through the work of a dedicated development group established in 2024 with a panel of intern...
Back to Newsroom